We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment ...

BofA Securities has recently raised Incyte Corp (INCY) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on October 1, 2024, Wolfe Research had initiated the stock ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation and has declared relationships with AbbVie, ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat.com reports. One ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

On Wednesday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $73.93 which represents a slight increase of $0.33 or 0.45% from the prior close of $73.6. The stock opened at $73.6 and ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...